Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GeneDx Holdings ( (WGS) ) has provided an update.
On September 17, 2025, GeneDx Holdings Corp. appointed Thomas Fuchs as a Class I director, expanding its Board from 7 to 8 members. Dr. Fuchs, who is the SVP and Chief AI Officer at Eli Lilly and Company, brings extensive experience in artificial intelligence and machine learning, which could enhance GeneDx’s strategic direction and operational capabilities.
The most recent analyst rating on (WGS) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on GeneDx Holdings stock, see the WGS Stock Forecast page.
Spark’s Take on WGS Stock
According to Spark, TipRanks’ AI Analyst, WGS is a Neutral.
GeneDx Holdings’ overall score is driven by strong financial performance and positive earnings call sentiment, indicating operational improvements and growth potential. However, the high P/E ratio suggests overvaluation, and technical indicators point to overbought conditions, which could limit upside potential.
To see Spark’s full report on WGS stock, click here.
More about GeneDx Holdings
Average Trading Volume: 844,489
Technical Sentiment Signal: Buy
Current Market Cap: $3.67B
Find detailed analytics on WGS stock on TipRanks’ Stock Analysis page.